BRCA1 or BRCA2 pathogenic variant (germline OR somatic) in high-grade serous ovarian carc...
Детермінований перегляд YAML-сутності з джерельної бази. Клінічний авторитет лишається за вказаними source ID та статусом клінічного sign-off.
| ID | RF-OVARIAN-BRCA-MUT-ACTIONABLE |
|---|---|
| Тип | Тривожна ознака |
| Статус | переглянуто 2026-04-27 | очікує клінічного підпису |
| Хвороби | DIS-OVARIAN |
| Джерела | SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 SRC-SOLO1-MOORE-2018 SRC-SOLO2-PUJADE-LAURAINE-2017 |
Походження тривожної ознаки
| Визначення | BRCA1 or BRCA2 pathogenic variant (germline OR somatic) in high-grade serous ovarian carcinoma — ~20-25% prevalence (15% germline + ~7% somatic). Olaparib maintenance after platinum-based 1L (SOLO-1 — mPFS 56.0 vs 13.8 mo BRCA-mut) is treatment-defining; rucaparib + niraparib alternatives. SOLO-2 — 2L+ relapse maintenance. |
|---|---|
| Клінічний напрям | intensify |
| Категорія | high-risk-biology |
| Змінює алгоритм | ALGO-OVARIAN-ADVANCED-1L, ALGO-OVARIAN-2L |
Логіка спрацьовування
{
"any_of": [
{
"finding": "brca1_brca2_pathogenic",
"value": true
},
{
"finding": "brca1_status",
"value": "pathogenic"
},
{
"finding": "brca2_status",
"value": "pathogenic"
},
{
"finding": "brca1_brca2_tumor",
"value": "pathogenic"
},
{
"finding": "brca1_brca2_germline",
"value": "pathogenic"
}
],
"type": "biomarker"
}
Нотатки
Tumor-tissue testing identifies somatic BRCA missed by germline-only testing — both germline (blood) AND tumor BRCA testing recommended at diagnosis for all newly diagnosed advanced ovarian. Germline finding triggers cascade testing of relatives + risk-reducing surgery counseling. Olaparib + bevacizumab (PAOLA-1) extended benefit in HRD-positive (incl. BRCA-mut) cohort. RF coexists with RF-OVARIAN-HRD-ACTIONABILITY — BRCA-mut is the BRCA-specific subset; HRD covers both BRCA + GIS-positive non-BRCA cases.
Де використовується
Algorithms
ALGO-OVARIAN-2L- ALGO-OVARIAN-2LALGO-OVARIAN-ADVANCED-1L- ALGO-OVARIAN-ADVANCED-1L
Тривожна ознака
RF-OVARIAN-HRD-POSITIVE-ACTIONABLE- Homologous Recombination Deficiency (HRD)-positive high-grade serous ovarian carcinoma (B...RF-PAN-BRCA-SOMATIC-PARPI-CANDIDATE- Somatic (tumor-only) BRCA1 or BRCA2 pathogenic variant identified on tumor NGS — pan-tumo...